Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disease Clear all
Completed Not applicable Interventional Results available

Avastin for PDR (Proliferative Diabetic Retinopathy)

NCT01270542
View directory record Official record
Conditions
Retinal Detachment, Diabetic Retinopathy
Interventions
Avastin (bevacizumab), Sham injection
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 24, 2026, 4:32 AM EDT
Completed No phase listed Observational

The Course of Response to Focal Photocoagulation for DME

NCT00442156
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Laser photocoagulation
Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Palm Springs, California • Fort Lauderdale, Florida • Fort Myers, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 24, 2026, 4:32 AM EDT
Completed Phase 3 Interventional

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

NCT00000688
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
San Diego, California • San Francisco, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 24, 2026, 4:32 AM EDT
Terminated No phase listed Observational

Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa (adRP)

NCT02926092
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Observation
Diagnostic Test
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 24, 2026, 4:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Modified P200TE Data Collection

NCT07796230
View directory record Official record
Conditions
Retina Disease
Interventions
imaging device
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 24, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene

NCT03780257
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
QR-421a, Sham-procedure (dose cohort 1&2 only)
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 24, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

NCT00002437
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Cidofovir, Probenecid
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional Results available

Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma

NCT01293539
View directory record Official record
Conditions
Retinoblastoma
Interventions
Melphalan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 24, 2026, 4:32 AM EDT
Not listed No phase listed Observational

Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

NCT06400368
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Not listed
Lead sponsor
NeuroVision Imaging
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 24, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Results available

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

NCT01003691
View directory record Official record
Conditions
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
Interventions
RN6G, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
24
States / cities
Campbell, California • Los Gatos, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 24, 2026, 4:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

NCT01694940
View directory record Official record
Conditions
Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
16
States / cities
San Diego, California • Stanford, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 24, 2026, 4:32 AM EDT
Completed No phase listed Observational

OPTDR01 Feasibility for Automated Diabetic Retinopathy Detection

NCT06343350
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes
Interventions
OPTDR01 software application
Device
Lead sponsor
Optain Health
Industry
Eligibility
22 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Chula Vista, California • San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 4:32 AM EDT
Completed No phase listed Observational

Global Patient Registry of Inherited Retinal Diseases

NCT05957276
View directory record Official record
Conditions
Inherited Retinal Diseases
Interventions
Standard of Care
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Years and older
Enrollment
886 participants
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 24, 2026, 4:32 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

NCT03913143
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions
sepofarsen, Sham
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
8 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 24, 2026, 4:32 AM EDT
Completed No phase listed Observational

39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity

NCT01993043
View directory record Official record
Conditions
ROP Threshold
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Weeks to 40 Weeks
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
2
States / cities
Houston, Texas • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 24, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000

NCT00784225
View directory record Official record
Conditions
Cataract, Macular Degeneration
Interventions
selenium, vitamin E, vitamin E placebo, selenium placebo
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
50 Years to 120 Years · Male only
Enrollment
13,475 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 24, 2026, 4:32 AM EDT
Withdrawn Phase 2 Interventional

Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids

NCT00846625
View directory record Official record
Conditions
Macular Edema, Uveitis
Interventions
triamcinolone, ranibizumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 24, 2026, 4:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Eye Institute Biorepository for Retinal Diseases

NCT01496625
View directory record Official record
Conditions
Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 4:32 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Corticosteroid for Diabetic Macular Edema (DME) Study

NCT07843849
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Diabetic Retinopathy
Interventions
Intravitreal dexamethasone implant
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion

NCT01028248
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Santa Barbara, California • Santa Maria, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 24, 2026, 4:32 AM EDT
Not listed Phase 2 Interventional

Analysis of Aqueous and Vitreous Humor

NCT02067013
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma
Interventions
Ranibizumab, No Ranibizumab
Drug · Other
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 24, 2026, 4:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atlas of Retinal Imaging in Alzheimer's Study

NCT03862222
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
Interventions
Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
Other · Diagnostic Test · Genetic
Lead sponsor
University of Rhode Island
Other
Eligibility
55 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
4
States / cities
Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 24, 2026, 4:32 AM EDT
Completed No phase listed Observational

The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis

NCT00341172
View directory record Official record
Conditions
AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years to 100 Years
Enrollment
2,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 24, 2026, 4:32 AM EDT
Completed No phase listed Observational

Mechanisms of Diabetic Kidney Disease in American Indians

NCT01878045
View directory record Official record
Conditions
Nervous System, Diabetic Kidney Disease, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 4:32 AM EDT